Related Experiment Videos
Preoperative treatment with azlocillin in complicated urinary tract infections
Abstract:
Eighteen patients, aged 18-84 years, with complicated urinary tract infections admitted to hospital were treated preoperatively with azlocillin (Securopen) for 5 to 10 days. Two patients having chronic pyelonephritis were not operated. Isolates bacteria were Pseudomonas aeruginosa (14), Proteus mirabilis (3), Escherichia coli (2) and Klebsiella spp. (1). Serum concentrations and urine recovery were measured on the fifth day of treatment. The mean serum half-life was 1.85 h and the mean value of the urine recovery 47% of the single dose. On the 5th day of treatment the urine was sterile in 80% of the patients. In 12 patients (60%) the urine was still sterile when controlled 2-6 months after operation and prophylactic postoperative treatment with nitrofurantoin or trimethoprim-sulfamethoxazole.
Insights
Azlocillin effectively treated complicated urinary tract infections in hospitalized patients, achieving sterile urine in 80% by day five. Long-term follow-up showed sustained sterile urine in 60% post-operation.
Area of Science:
- Pharmacology
- Infectious Diseases
- Urology
Background:
- Complicated urinary tract infections (cUTIs) pose significant clinical challenges.
- Bacterial resistance necessitates effective antimicrobial agents for cUTIs.
Purpose of the Study:
- To evaluate the efficacy of azlocillin in treating complicated urinary tract infections.
- To assess azlocillin's pharmacokinetic profile and impact on bacterial eradication.
Main Methods:
- Eighteen hospitalized patients with cUTIs received preoperative azlocillin (5-10 days).
- Bacterial isolates included Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli, and Klebsiella spp.
- Serum concentrations and urine recovery were measured on day five; long-term sterile urine rates were assessed post-operation.
Main Results:
- Azlocillin achieved sterile urine in 80% of patients by day five.
- Mean serum half-life was 1.85 hours; mean urine recovery was 47% of the single dose.
- 60% of patients maintained sterile urine 2-6 months post-operation with prophylactic treatment.
Conclusions:
- Azlocillin demonstrates significant efficacy in treating complicated urinary tract infections.
- The pharmacokinetic profile supports its use in managing cUTIs.
- Sustained sterile urine rates suggest favorable long-term outcomes with appropriate follow-up care.